Exploring the Association of Lipid-Lowering Drugs with Diabetes: A Comprehensive Review

The association between lipid-lowering drugs and diabetes has been extensively investigated due to its clinical significance. This review aims to elucidate the complex relationship between lipid-lowering medications and the risk of diabetes development. Through a comprehensive analysis of existing literature, it examines the underlying mechanisms, epidemiological evidence and clinical implications of this association. In review methodologically synthesizes findings from observational studies, randomized controlled trials and meta-analyses to provide a nuanced understanding of the topic. The study scrutinizes the effects of various classes of lipid-lowering drugs, including statins, fibrates and PCSK9 inhibitors, on glucose metabolism and insulin sensitivity. Additionally, evaluate the impact of dose, duration and patient characteristics on the risk of incident diabetes. Current study analysis underscores the importance of individualized treatment approaches in managing dyslipidemia, considering both cardiovascular benefits and potential diabetogenic effects. This study concludes by offering recommendations for clinicians to optimize lipid-lowering therapy while minimizing the risk of diabetes onset. This review serves as a valuable resource for healthcare professionals navigating the complexities of lipid management in clinical practice.